fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Large, Small & Micro Cap Stocks Charge Higher This Week – $ADT $INDP $MODD $OKLO $NVDA $RKLB $TSMC Rise!

By John F. Heerdink, Jr.

It seems Wall Street decided to throw a week-long party, and all the major indices were invited! Let’s break down the festivities:

Dow Jones Industrial Average: The Life of the Party

The Dow Jones Industrial Average was the star of the show this week, strutting its stuff with a 0.9% gain. It’s like the index found its groove on the dance floor and just couldn’t stop moving. This marks the Dow’s sixth consecutive week of gains, its longest winning streak since December. Who knew blue chips could be so hip?

S&P 500: Not to Be Outdone

Not wanting to be left out of the fun, the S&P 500 joined the conga line with a 0.8% increase for the week.  This broad-market index also celebrated its sixth straight week of gains, matching the Dow’s impressive streak. It’s like the S&P 500 and the Dow are in a friendly competition to see who can keep the party going longer.

Nasdaq Composite: The Tech-Savvy Reveler

The tech-heavy Nasdaq Composite didn’t want to be the wallflower at this market soirée. It chipped in with a respectable 0.7% weekly gain.  While it might not have been leading the conga line, it certainly wasn’t sitting this dance out. With help from Netflix’s post-earnings pop, the Nasdaq managed to keep pace with its index buddies

Russell 2000 & The Surprise Guest (Micros)

But wait, who’s that crashing the party? It’s the Russell 2000, representing the small-cap stocks, and it’s making quite an entrance! This plucky index outperformed its larger counterparts with a whopping 1.9% weekly gain.  It’s like the Russell 2000 showed up fashionably late but immediately became the life of the party.In the end, it was a week of celebration for all major indices, with each one contributing to the market’s upbeat mood. Whether you prefer the steady reliability of the Dow, the broad appeal of the S&P 500, the tech excitement of the Nasdaq, or the spunky energy of the Russell 2000, there was something for everyone in this market fiesta. Let’s see if they can keep the party going next week, or if someone will eventually call the noise complaint! By the way, the micro mini stocks represented in the iShares Micro-Cap ETF (IWC) closed at $128.36, +3.56% over the last 5-days. The SPDR S&P 500 Biotech ETF (XBI) rose 1.17% over the last 5-days and is up +11.80% YTD. 

A Few Tech Titans

* Apple (AAPL) closed at $235, up 3.27% for the week.  

* NVIDIA (NVDA) added another 2.37% market moving jump over the five-day period to end at $134.80, buoyed by the company’s ongoing dominance in AI chips and data center solutions continued to drive investor enthusiasm.

* Tesla (TSLA) recovered 1.33% over the course of 5-days.

* Dell Technologies (DELL) closed at $126.46, -.99% over the last 5-days.

* Advanced Micro Devices (AMD) closed at $155.97, -7.10% over the last 5-days.

* Taiwan Semiconductor (TSMC) beat quarterly expectations and up +7.76% once the last 5-days. 

The 20% Club: More Exclusive Than Your Local Country Club

We’re all excited about potentially joining the “20% Club” for the second year running. It’s like getting a hole-in-one twice in a row – rare, impressive, and bound to make your golfing buddies jealous. But let’s not get ahead of ourselves; the year’s not over, and the market could still trip over its own shoelaces. Now, 20% isn’t some magical number bestowed upon us by the Stock Market Gods. It’s just a nice, round figure that makes us feel warm and fuzzy inside. Heck, there have been nine years since 1950 where the market gained between 15% and 20%. That’s like getting an A- instead of an A+. Still pretty darn good, right?

The Two-Year Tango: A Rare Dance Indeed

If 2024 keeps its groove and ends up over 20%, we’ll be doing the two-year tango – a dance move so rare, it makes the moonwalk look commonplace. Historically, after such a performance, stocks often keep the party going into the third year, but with less enthusiasm. It’s like going from dancing on tables to a gentle swaying in place.

The ‘Crystal Ball’ of Fundamentals?

So, what’s the secret sauce for 2025? Well, it’s a blend of economic growth (how fast is the money train moving?), Fed policy (are they being stingy or generous with the interest rates?), and corporate profits (are companies rolling in dough or scraping by?).Let’s compare our current situation to the five previous times stocks did the 20% two-step: As you can see, we’re not quite matching up to those historical highs. But hey, who needs historical precedent when you’ve got memes and AI, right? Remember, folks, past performance doesn’t guarantee future results. The stock market is like a box of chocolates – you never know what you’re gonna get, but it’s probably going to give you a sugar rush followed by a crash. Happy investing, and may the odds be ever in your favor!

VP Watchlist Updates

Now let’s check these nuggets below!


Oklo Inc. (NYSE: OKLO, $18.23, +99.23% over the last 5-days), an advanced fission power technology and nuclear fuel recycling company, today announced that the U.S. Department of Energy (DOE) has approved the Conceptual Safety Design Report (CSDR) for the Aurora Fuel Fabrication Facility at Idaho National Laboratory (INL). This approval is a key milestone as Oklo advances toward its goal of utilizing recovered nuclear material to fuel its first commercial Aurora powerhouse. The Aurora Fuel Fabrication Facility is expected to fabricate fuel for Oklo’s Aurora power plant to be sited at INL. The facility will use high assay low enriched uranium that has been recovered from used Experimental Breeder Reactor-II fuel. “We are proud of our collaboration with INL and DOE as we move closer to turning on our first commercial plant that uses this recovered nuclear fuel in just a few years,” said Jacob DeWitte, co-founder and CEO of Oklo. Oklo is uniquely positioned with a secured fuel supply, site use permit, significant regulatory traction, and supply chain development to support the first deployment of its Aurora powerhouse.


 

The global diabetes care market, valued at $18.9 billion in 2023, is projected to reach $35.8 billion by 2028, with the insulin pump segment expected to grow from $5.26 billion to $21.65 billion by 2032. As reported by Fortune Business Insights, this rapid growth is driven by increasing diabetes prevalence and technological advancements in insulin delivery devices.

Modular Medical, Inc. (NASDAQ: MODD, $2.21, +3.27% over the last 5-days and is up 108.49% over the last year), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Their mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond “superusers” and providing “diabetes care for the rest of us.” Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

In October, Modular’s CEO was interviewed by Carole Sullivan on the Today In Nashville program affiliated with Channel 4 WSMV. The segment is called “New Tools for Treating Diabetes by Modular Medical.” You may watch the video now at this link.

On September 18, Modular Medical announced the issuance of U.S. Divisional Patent Application No. 17/968,599. “The issuance of this patent and the associated claims represent a major step in our efforts to protect the intellectual property in the MODD1 pump platform,” stated Jeb Besser, CEO of Modular Medical. “Some of the key features of our novel, low-cost and accurate insulin delivery technology are now protected by this important issued U.S. patent, which we believe represents a significant new barrier to entry. Our eight families of patents around our pump are an important part of our strategic value and market positioning, and we look forward to announcing further issuances on our portfolio in the future.”

On September 11, Modular Medical’s CEO Jeb Besser presented at Tribe Public’s Webinar Presentation and Q&A Event titled “Diabetes, Obesity, GLP-1, & The MODD-1 Opportunity.” The event video has now been viewed over 47,000 times and can now be viewed below:

On Wednesday, September 4, Modular announced it has received U. S. Food and Drug Administration (“FDA”) clearance to market and sell its MODD1 pump in the United States. With its commercial manufacturing infrastructure substantially established, the Company anticipates the MODD1 should be available for sale in early 2025.

 

James (Jeb) Besser, CEO of Modular Medical (NASDAQ: MODD)

“For too long, the benefits of superior glycemic control achieved by insulin pumps have, due to cost and complexity, been restricted to only the most sophisticated, motivated and well-insured users. The goal of Modular Medical has always been to change this by making diabetes technology accessible and affordable to underserved communities. We seek to make the experience of going ‘on a pump’ simpler and less intimidating and to widen the base beyond the current pump users,” said Jeb Besser, CEO of Modular Medical.


Shares of Indaptus Therapeutics, Inc. (Nasdaq: INDP) closed at $1.5097, +18.87% over the last 5-days.  Indaptus is a company with the ability to harness both the body’s innate and adaptive immune responses, believes that they are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (Nod)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The products are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy products represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts.

On October 15, Indaptus Therapeutics, Inc. (Nasdaq: INDP) provided an update regarding key clinical advancements in its Phase 1 trial of lead drug candidate Decoy20. The Safety Review Committee examined weekly administration data at the lower Decoy20 dose and cleared unrestricted enrollment of patients at this dose. The safety profile observed to date remains aligned with Decoy20’s expected mechanism of action. The most clinically relevant treatment-related adverse events include Grade 2 Infusion Related Reaction and Grade 2 Hypotension, both of transient duration.  Jeffrey Meckler, Chief Executive Officer, added, “We continue to gather robust data on Decoy20, which remains consistent with our expectations from preclinical studies. We believe the continuation of this trial, and the eventual initiation of combination therapy studies presents an important opportunity to have a potentially significant impact on cancer immunotherapy. We look forward to sharing these results in the coming months.”

On Aug. 12, Indaptus announced financial results for the second quarter ended June 30, 2024, and provided a corporate update. Jeffrey Meckler, Indaptus Therapeutics’ Chief Executive Officer, commented, “During the second quarter we had multiple opportunities to share our findings regarding our Phase 1 clinical trial to date, and to demonstrate the unique approach that our Decoy platform offers. These included impactful conferences such as the American Association for Cancer Research (AACR) annual meeting and the American Society of Clinical Oncology (ASCO) annual meeting, which are considered among the top annual oncology conferences. Further, our founder was once again recognized by the industry when he was named chair of the STING & TLR-Targeted Therapies Summit. We are encouraged by the results we have reported, along with the data we are seeing as we continue the multi-dose stage of the Phase 1 clinical trial. As Decoy20 continues to be well-tolerated in our Phase 1 clinical trial, we expect to progress to dosing multiple patients simultaneously. This will increase the data we receive and, as a result, is expected to accelerate the progress of the trial. We look forward to demonstrating continued impactful outcomes in the second half of the year.”

Key recent highlights:

  • Completed a $3 million registered direct offering and concurrent private placement on August 8, 2024, for net proceeds of approximately $2.5 million

  • Advancing clinical trial from single to weekly doses of Decoy20, the company completed one month of weekly dosing in three patients at the 3-x 10^7 Decoy20 dose

  • Completed a single dose cohort at the higher dose of 7 x 10^7 Decoy20 and intend to initiate weekly dosing later this year

  • Presented poster outlining data from 3 x 10^7 and 7 x 10^7 dose at the ASCO annual meeting on June 1, 2024, in Chicago

  • Presented poster outlining new mechanism of action data for Decoy platform at the AACR annual meeting in April 2024

  • Founder and Chief Scientific Officer, Michael Newman, Ph.D. presented additional data on the Company’s lead product candidate, Decoy20, at the 5th Annual STING & TLR-Targeted Therapies Summit in San Diego on June 19-20, 2024, where he was also named chair of the Summit


Lantern (LTRN) closed at $3.44, -1.15% over the last 5-days and is up +2.08% over the last year.  Lantern is an Artificial Intelligence (AI) firm that is transforming the cost, pace, and timeline of oncology drug discovery and development and specifically is developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs.

On October 15, Lantern Pharma announced that the FDA has granted Fast Track Designation for investigational drug candidate, LP-184, for treatment of Glioblastoma. LP-184 is currently in a Phase 1A clinical trial designed to evaluate the safety and tolerability of the synthetically lethal investigational drug candidate in a broad range of solid tumors, including Glioblastoma (GBM). LP-184 was optimized and advanced in part with Lantern’s AI platform, RADR®, to aid in the validation of mechanisms that could be exploited in the clinical setting to eradicate challenging cancers, and uncover insights in targeted patient populations. RADR® is Lantern’s AI platform for cancer therapy discovery, development and rescue with over 100 billion data points and aiding in the development of both Lantern’s portfolio and development initiatives with Lantern’s collaborators. Fast Track Designation is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need. Fast Track Designation for LP-184 (STAR-001) recognizes Glioblastoma (GBM) as a serious condition impacting more than 13,000 U.S. adults each year and approximately 300,000 globally. A phase 1b/2a clinical trial for recurrent GBM is targeted to start in late 2024/early 2025. LP-184, which will be developed as STAR-001 for CNS and other neuro-oncology indications by Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma, has the potential to be the first new drug for treating GBM in more than 20 years.

On September 23, Lantern announced that the company has been granted three rare pediatric disease designations (RPDD) by the FDA. Lantern was granted these rare pediatric disease designations in: malignant rhabdoid tumors (MRT), rhabdomyosarcoma (RMS), and hepatoblastoma. Rare pediatric diseases are defined by the FDA as serious or life-threatening conditions primarily affecting children under 18, with fewer than 200,000 cases in the U.S. A key benefit of obtaining a RPDD is the potential to receive a priority review voucher following FDA approval of a product with RPDD if the marketing application submitted for the product satisfies certain conditions, including approval prior to September 30, 2026 unless changed by legislation. These vouchers, often called “golden tickets,” can significantly expedite the review process for future NDAs or biologic license applications, reducing the standard review time from about ten months to six. Sponsors can either use these vouchers themselves or sell them to other companies. These vouchers, in the recent past, have commanded sales prices of approximately $100 million USD.

 

Panna Sharma is the President, CEO, and Board Member of Lantern Pharma Inc.

“At Lantern, we’re harnessing AI and data-driven approaches to revolutionize cancer drug development, aiming to dramatically reduce costs, accelerate timelines, and enhance precision in bringing new therapies to patients. Our recent breakthrough in identifying three additional, high-potential indications for LP-184 in pediatric cancers exemplifies this progress. We believe that ‘AI for good’ should address both blockbuster opportunities as well as rare, often overlooked pediatric cases. The FDA’s Rare Pediatric Disease designation for these three potential programs is a testament to this commitment. We’re acutely aware that patients and their families are relying on innovators like us to speed up therapy development. These designations mark a crucial step forward in advancing our expanding portfolio of pediatric programs targeting these devastating and rare cancers. It reinforces our dedication to transforming hope into tangible solutions for those who need them most,” stated Panna Sharma, CEO and President of Lantern Pharma.


On August 9, announced operational highlights and financial results for the second quarter 2024, ending June 30, 2024 highlighting the following:

  •  Active clinical trials across three AI-guided drug candidates with additional ADC-based preclinical molecules in evaluation for development.
  • Preliminary patient data and clinical readouts for Phase 2 LP-300 Harmonic™ Trial released showing an 86% clinical benefit rate in the initial 7 patient safety lead-in cohort.
  • Issued a Certificate of Patent by the Japanese Patent Office directed to Lantern Pharma’s drug candidate LP-284, including claims covering the new molecular entity.
  • Phase 1 clinical trials for both synthetic lethal drug candidates, LP-184 and LP-284, continue to advance with no dose-limiting toxicities observed in any of the patient cohorts enrolled and over 40 patients dosed to-date.
  • Achieved significant advancement towards key milestone in the development of molecular diagnostic for use with drug candidate LP-184 in future oncology clinical trials to improve patient selection and stratification.
  • Launched strategic drug development collaboration leveraging our AI platform, RADR®, with Oregon Therapeutics to optimize the development of first-in-class drug candidate XCE853 – a potent inhibitor of cancer metabolism.
  • Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma focused on CNS and brain cancers advanced with initiating site selection and feasibility for a Phase 1B/Phase 2 trial in recurrent GBM with drug candidate, STAR-001.
  • Launched Webinar Wednesdays, a webinar series that focuses on the areas of artificial intelligence and oncology drug development with leading physicians, scientists and Lantern collaborators.
    Approximately $33.3 million in cash, cash equivalents, and marketable securities as of June 30, 2024.


Eupraxia Pharmaceuticals (EPRX, $2.51, +4.58% over the last 5-days) is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver targeted, long-lasting activity with fewer side effects. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic (PK) profiles. This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery methods.

On October 15, Eupraxia announced that Lancet Rheumatology, a leading independent, peer-reviewed journal committed to sharing progressive content relevant to rheumatology specialists worldwide, recently published Eupraxia’s Phase 2 data from its SPRINGBOARD trial evaluating EP-104IAR for the treatment of knee osteoarthritis. Publication of Eupraxia’s Phase 2b data in Lancet Rheumatology, a distinguished and respected journal, raises the profile of EP-104IAR. As outlined in Lancet Rheumatology, Eupraxia’s EP-104IAR imparts clinically significant and durable pain relief, while also having minimal changes in glucose and cortisol, along with stable fluticasone proportionate concentrations in plasma. The U.S. Centers for Disease Control and Prevention estimates that knee osteoarthritis affects more than 30 million people in the U.S. alone. You may read the Lancet Publication regarding Eupraxia at this link. 

Eupraxia is presented a poster at the United European Gastroenterology (“UEG”) Week 2024 held in Vienna, Austria on October 12-15, 2024.

On September 11, Eupraxia announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (“EoE”). The results announced today from the fourth cohort of the RESOLVE trial, using Eupraxia’s DiffuSphere™ technology for EoE, are derived from twelve 2.5 mg injections of EP-104GI (total dose of 30 mg) administered to less than two-thirds of each patient’s lower esophagus. The data show:

  • Straumann Dysphagia Index (“SDI”)1, a patient-reported outcome measure designed to assess symptom severity, was lower for all three patients post-administration with peak reductions up to four points (67% from baseline). At 12 weeks post-administration, SDI was reduced by a mean of 45% or 3.3 points – a level comparable with currently approved therapies.
  • Eosinophilic Esophagitis Histology Scoring System (“EoEHSS”)2 scores, which evaluate the severity and extent of EoE, showed the largest percent reduction of any cohort to date, with a mean 39% reduction in Composite Stage and a mean 37% reduction in Composite Grade at 12 weeks – a level comparable with currently approved therapies.
  • Using data from four biopsy sites, which is consistent with the U.S. Food and Drug Administration (“FDA”) Guidance for Developing Drugs for the Treatment of EoE, the mean reduction in Peak Eosinophil Counts (“PEC”)3 was 67% at 12 weeks.
 

 

On July 9, a Tribe Public CEO Presentation and Q&A Webinar Event titled Exploring The Rapid Rise Of Osteoarthritis”  was held with James A. Helliwell, MD, Director and Chief Executive Officer of Eupraxia Pharmaceuticals (NASDAQ: EPRX). Please view the event video below:


On Aug. 7, Eupraxia announced its financial results for the second quarter of 2024. Dr. James Helliwell, CEO of Eupraxia stated, “Our eosinophilic esophagitis (“EoE”) clinical program is making excellent progress, as additional safety and efficacy data from our ongoing RESOLVE study continues to suggest that EP-104GI could represent a significant improvement over currently approved therapies for this debilitating condition. In addition, during the second quarter, we presented data at two medical meetings highlighting the potential of our candidate for the treatment of knee osteoarthritis (“OA”), EP-104IAR, which also holds the potential to advance the current standard of care in OA. “Looking ahead, we anticipate reporting new data from the fourth cohort of the RESOLVE study in the near term and we continue to engage prospective partners for possible licensing of the EP-10IAR program. We look forward to engaging with the U.S. Food and Drug Administration in the fourth quarter of 2024 on the EP-104GI program and potentially expanding our gastrointestinal trials into the U.S. With two clinical-stage assets each having the potential to represent a meaningful improvement over currently approved therapies, we believe Eupraxia remains well positioned to create shareholder value.” Learn more here. 

On Aug. 2, Eupraxia announced entry into a new C$12 million convertible debt facility. Under the Convertible Debt Facility, Yabema Capital Limited and other current Eupraxia shareholders (together, the “Lenders”) will make available for drawdown an aggregate amount of C$12 million for a period of 120 days following entry into the agreement. The decision to draw on the facility within 120 days of closing is at the discretion of Eupraxia and is subject to the full and final release of the SVB Facility (as defined below), originally agreed to on June 21, 2021. The aggregate unpaid principal amount and any accrued and unpaid interest thereon will be convertible at each individual lender’s discretion into Eupraxia common shares (the “Common Shares”), at a conversion price equal to C$4.84375 per Common Share. The conversion is further subject to certain threshold limitations with respect to each lender’s aggregate ownership of the Common Shares. “The new convertible debt facility provides an important source of additional funding from long term, supportive investors, and creates greater stability to Eupraxia’s cap structure as we continue to advance our clinical programs in eosinophilic esophagitis and osteoarthritis,” said Dr. James Helliwell, Chief Executive Officer of Eupraxia. The Convertible Debt Facility is subject to final approval of the Toronto Stock Exchange.

 

Shares of ADT Inc. (ADT), the most trusted brand in smart home and small business security, closed at $7.09, +3.05% over the last 5-days and +3.96% YTD.

On Oct. 7, Home security firm ADT Inc said on Monday an unauthorized actor had illegally accessed its network using credentials obtained through a third-party business partner. ADT said it is working closely with federal law enforcement and external cybersecurity experts to help with its response to the incident. The company has also implemented countermeasures to help safeguard its information technology assets and operations, which have resulted in some disruptions to ADT’s information systems, the company said in the filing.

 

Rocket Lab USA, Inc. (Nasdaq: RKLB, $10.81, +11.44%) on Friday and +95.48% YTD), a global leader in launch services and space systems, recently announced that they successfully launched its 53rd Electron mission and deployed five satellites to Low Earth Orbit for French Internet-of-Things (IoT) company Kinéis. A KeyBanc analyst raised their price target to $11 on September 27. 

QUOTE OF WEEK


“I can, therefore I am.” – Simone Weil
 

Investing & Inspiration

  1. “Art is the right hand of Nature. The latter has only given us being, the former has made us men.” – Friedrich Schiller
  2. “To begin, begin.” –  William Wordsworth
  3. “Nature does not hurry, yet everything is accomplished.” – Lao Tzu
  4. “The end of labor is to gain leisure.” – Aristotle
  5. “People are not disturbed by things, but by the view they take of them.” – Epictetus
  6. “Have patience. All things are difficult before they become easy.” – Saadi
  7. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
  8. “The traveler sees what he sees, the tourist sees what he has come to see.” – Gilbert K. Chesterton
  9. “The only true wisdom is in knowing you know nothing.” – Socrates
  10. “Courage is knowing what not to fear.”– Plato
  11. “The home is the chief school of human virtues.” – William Ellery Channing
  12. “Be brave. Take risks. Nothing can substitute experience.” – Paulo Coelho
  13. “There are no shortcuts in evolution.” – Louis D. Brandeis
  14. “A friend may well be reckoned the masterpiece of nature.” –  Ralph Waldo Emerson
  15. “Nature uses as little as possible of anything.” – Johannes Kepler
  16. “Every new beginning comes from some other beginning’s end.” – Seneca
  17. “Nothing ever becomes real till it is experienced.” – John Keats
  18. “Nobody who ever gave his best regretted it.” – George Halas
  19. “Honest disagreement is often a good sign of progress.” – Mahatma Gandhi
  20. “A leader is one who knows the way, goes the way, and shows the way.” – John C. Maxwell
  21. “They always say time changes things, but you actually have to change them yourself.” – Andy Warhol
  22. “The secret of happiness is something to do.” – John Burroughs
  23. “The world of reality has its limits; the world of imagination is boundless.”
  24. “You begin with the possibilities of the material.” – Robert Rauschenberg
  25. “The only Zen you can find on the tops of mountains is the Zen you bring up there.” – Robert M. Pirsig
  26. “Leadership is the capacity to translate vision into reality.” – Warren Bennis
  27. “A man should always consider how much he has more than he wants.” – Joseph Addison
  28. “Happiness is good health and a bad memory.” –  Ingrid Bergman
  29. “We pass through this world but once.” – Stephen Jay Gould
  30. “Christmas waves a magic wand over this world, and behold, everything is softer and more beautiful.” – Norman Vincent Peale
  31. “Nothing can have value without being an object of utility.” – Karl Marx
  32. “Always turn a negative situation into a positive situation.” – Michael Jordan
  33. “Courage is found in unlikely places.” – J. R. R. Tolkien
  34. “One that would have the fruit must climb the tree.” – Thomas Fuller
  35. “Someone is sitting in the shade today because someone planted a tree a long time ago.” – Warren Buffett
  36. “We relish news of our heroes, forgetting that we are extraordinary to somebody too.” – Helen Hayes
  37. “A life spent making mistakes is not only more honorable, but more useful than a life spent doing nothing.” – George Bernard Shaw
  38. “Everything in the world may be endured except continual prosperity.”  – Johann Wolfgang von Goethe
  39. “Nine-tenths of wisdom is being wise in time.” – Theodore Roosevelt
  40. “Time is money.” – Benjamin Franklin
  41. “Change before you have to.” – Jack Welch
  42. “Our deeds determine us, as much as we determine our deeds.” – George Eliot
  43. “The Universe is under no obligation to make sense to you.” – Neil deGrasse Tyson
  44. “Care and diligence bring luck.” – Thomas Fuller
  45. “Nobody made a greater mistake than he who did nothing because he could do only a little.” – Edmund Burke
  46. “A man who is a master of patience is master of everything else.” – George Savile
  47. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  48. “Endurance is nobler than strength, and patience than beauty.” – John Ruskin
  49. “Act as if what you do makes a difference. It does.” – William James
  50. “Let us be grateful to people who make us happy, they are the charming gardeners who make our souls blossom.” –  Marcel Proust
  51. “Strength and growth come only through continuous effort and struggle.” – Napoleon Hill
  52. “Science may never come up with a better office communication system than the coffee break.” – Earl Wilson
  53. “If everyone is moving forward together, then success takes care of itself.” – Henry Ford
  54. “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.”– Samuel Smiles
  55. “Patriotism is supporting your country all the time, and your government when it deserves it.” – Mark Twain
  56. “What would life be if we had no courage to attempt anything?” – Vincent Van Gogh
  57. “The biggest risk is not taking any risk… In a world that is changing really quickly, the only strategy that is guaranteed to fail is not taking risks.” – Mark Zuckerberg
  58. “Our lives improve only when we take chances – and the first and most difficult risk we can take is to be honest with ourselves.” – Walter Anderson
  59. “Action is the foundational key to all success.” – Pablo Picasso
  60. “Success is never final, failure is never fatal. It’s courage that counts.” – John Wooden
  61. “Innovation distinguishes between a leader and a follower.” – Steve Jobs
  62. “All the art of living lies in a fine mingling of letting go and holding on.” – Havelock Ellis
  63. “The size of your success is measured by the strength of your desire; the size of your dream; and how you handle disappointment along the way.” – Robert Kiyosaki
  64. “O, wind, if winter comes, can spring be far behind?” – Percy Bysshe Shelley
  65. “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk
  66. “Be true to your work, your word, and your friend.” – John Boyle O’Reilly
  67. “Believe in yourself! Have faith in your abilities! Without a humble but reasonable confidence in your own powers you cannot be successful or happy.” – Norman Vincent Peale
  68. “Surprise is the greatest gift which life can grant us.” – Boris Pasternak
  69. “Logic will get you from A to B. Imagination will take you everywhere.” – Albert Einstein
  70. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  71. “Do exactly what you would do if you felt most secure.” – Meister Eckhart
  72. “Life lived for tomorrow will always be just a day away from being realized.” – Leo Buscaglia
  73. “Wisdom is oftentimes nearer when we stoop than when we soar.” – Wordsworth
  74. “Take chances, make mistakes. That’s how you grow. Pain nourishes your courage. You have to fail in order to practice being brave.” – Mary Tyler Moore
  75. “A single twig breaks, but the bundle of twigs is strong.” – Tecumseh
  76. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  77. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  78. “The limits of the possible can only be defined by going beyond them into the impossible.” – Arthur C. Clarke
  79. “Be faithful in small things because it is in them that your strength lies.” – Mother Teresa
  80. “The future rewards those who press on. I don’t have time to feel sorry for myself. I don’t have time to complain. I’m going to press on.” – Barack Obama
  81. “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
  82. “No man was ever wise by chance.” – Lucius Annaeus Seneca
  83. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  84. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
  85. “It does not matter how slowly you go as long as you do not stop.” – Confucius

  86. “I want to put a ding in the universe.” – Steve Jobs

  87. “Research is creating new knowledge.” – Neil Armstrong

  88. “The reward for work well done is the opportunity to do more.” – Jonas Salk
  89. “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
  90. “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey
  91. “Success seems to be largely a matter of hanging on after others have let go.” – William Feather

  92. “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger
  93. “More business is lost every year through neglect than through any other cause.” – Rose Kennedy

  94. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes

  95. “A person who won’t read has no advantage over one who can’t read.” – Mark Twain
  96. “The best way out is always through.” – Robert Frost

  97. “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi
  98. “Without labor nothing prospers.” – Sophocles

  99. “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein
  100. “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt

  101. “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller

  102. “He who is brave is free.” – Lucius Annaeus Seneca
  103. “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk

  104. “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin

  105. “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll

  106. “He who knows that enough is enough will always have enough.” – Lao Tzu

  107. “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall
  108. “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama

  109. “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
  110. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  111. “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
  112. “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
  113. “You must do the things you think you cannot do.”- Eleanor Roosevelt
  114. “Success is dependent on effort.” – Sophocles
  115. “Nobody who ever gave his best regretted it.” – George Halas
  116. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
  117. “And when I breathed, my breath was lightning.” – Black Elk
  118. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
  119. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
  120. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  121. “We are an impossibility in an impossible universe.” – Ray Bradbury
  122. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
  123. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
  124. Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
  125. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
  126. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
  127. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
  128. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran 
  129. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
  130. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
  131. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
  132. “There is more to life than increasing its speed.” – Mahatma Gandhi
  133. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
  134. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
  135. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
  136. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
  137. “Life is too short for long-term grudges.” – Elon Musk
  138. There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  139. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  140. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  141. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  142. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  143. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  144. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  145. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  146. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  147. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  148. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
  149. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  150. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  151. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  152. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  153. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  154. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  155. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  156. “Delete the negative; accentuate the positive!” – Donna Karan
  157. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  158. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  159. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  160. “Everything has beauty, but not everyone sees it.” – Confucius
  161. A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  162. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  163. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  164. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  165. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  166. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
  167. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  168. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
  169. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  170. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  171. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  172. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  173. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  174. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  175. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  176. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  177. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  178. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  179. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  180. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  181. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  182. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  183. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  184. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese 
  185. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  186. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  187. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  188. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  189. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  190. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  191. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  192. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  193. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  194. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  195. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch 
  196. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  197. “The secret of getting ahead is getting started.” – Mark Twain
  198. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe


Post View Count : 501